姓       名: 项耀祖

行政职务：生物医药与技术系系主任

学       位: 博士

导师情况: 博士生导师

研究领域: 心血管疾病、中西医结合

研究方向:

1.心血管生物学与药理学

2.中西医结合防治冠心病

Email：yaozu.xiang@tongji.edu.cn

通讯地址：上海市杨浦区四平路1239号，同济大学生命科学与技术学院，邮编200092
 

个人简介
     项耀祖，同济大学长聘教授，博士生导师，国家优青。生物医药与技术系系主任。天津中医药大学医学学士、医学硕士；英国帝国理工学院分子血液学博士；美国耶鲁大学医学院博士后。主要从事心血管病发生机制和中西医干预研究。主持国家重点研发计划课题、国家自然科学基金优青项目、面上项目和联合项目等。代表性研究成果发表在Blood、JCI、PNAS、Protein & Cell、Cell Reports等学术期刊，申请或授权专利10项，主编专著2部。曾获ISTH Young Investigators Award、NSTH Science Prize、Imperial Rector’s Award等。

代表论文：

1. Li S, Wang K, Jiang K, Xing D, Deng R, Xu Y, Ding Y, Guan H, Chen LL, Wang D, Chen Y*, Bu W*, Xiang Y*. Brazilin-Ce nanoparticles attenuate inflammation by de/anti-phosphorylation of IKKβ. Biomaterials. 2024;305:122466.

2. Xu Y, Jiang K, Su F, Deng R, Cheng Z, Wang D, Yu Y, Xiang Y*. A transient wave of Bhlhe41+ resident macrophages enables remodeling of the developing infarcted myocardium. Cell Rep. 2023;42(10):113174.

3. Xu Y, Zhang C, Jiang K, Yang X, Chen F, Cheng Z, Zhao J, Cheng J, Li X, Chen X, Zhou L, Duan H, Huang Y*, Xiang Y*, Li J*. Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria. Acta Pharm Sin B. 2023;13(4):1671-1685. （封面论文）

4. Li Y, Tu Z, Chen F, Yang X, Deng R, Su F, Cheng Z, Li S, Ong SB, Wang D, Chen Y, Xiang Y*. Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediated pyroptosis. Phytomedicine. 2023;113:154743.

5. Xu Y, Jiang K, Chen F, Qian J, Wang D, Wu Y, Zhou C, Yu Y, Chen K, Hwa J, Yang B, Wang H, Xiang Y*. Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin. Basic Res Cardiol. 2022;117(1):47.

6. Jiang K, Tu Z, Chen K, Xu Y, Chen F, Xu S, Shi T, Qian J, Shen L, Hwa J, Wang D, Xiang Y*. Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acute myocardial infarction. J Clin Invest. 2022;132(1):e151268. （高被引论文）

7. Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, Shang H, Xiang Y*. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.Protein Cell. 2022;13(5):336-359.（封面论文）

8. Fu L, Xie C, Jin Z, Tu Z, Han L*, Jin M*, Xiang Y*, Zhang A*. The prokaryotic Argonaute proteins enhance homology sequence-directed recombination in bacteria. Nucleic Acids Res. 2019;47(7):3568-3579.

9. Wang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA, Herzog RI, Young LH, Qian L*, Hwa J*, Xiang Y*. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic Transl Sci. 2018;3(3):350-362.

10. Xiang Y*, Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WH, Lee SH, Leslie K, Spollett G, Liu Z, Herzog E, Herzog RI, Lu J, Martin KA, Hwa J*. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood. 2015;125(22):3377-87.（封面焦点论文）

11. Xiang Y, de Groot R, Crawley JT, Lane DA*. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). PNAS. 2011;108(28):11602-7.

12. Xiang YZ*, Xia Y, Gao XM, Shang HC, Kang LY, Zhang BL. Platelet activation, and antiplatelet targets and agents: current and novel strategies. Drugs. 2008;68(12):1647-64.

  本实验室常年招聘博士后，同时欢迎有浓厚科研兴趣的研究生、本科生报考和实习。